Skip to main content

Advertisement

SpringerLink
Log in

Serum sickness in a multiple sclerosis patient treated with ocrelizumab

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Karmacharya P, Poudel DR, Pathak R et al (2015) Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum 45(3):334–340

    Article  PubMed  Google Scholar 

  2. Moreira Ferreira VF, Kimbrough DJ, Stankiewicz JM (2021) A possible case of serum sickness after ocrelizumab infusion. Mult Scler 27:155–158

    Article  PubMed  Google Scholar 

  3. Rjeily NB, Nourbakhsh B, Mowry EM (2023) Serum sickness/serum sickness-like reactions following ocrelizumab infusion in 2 patients with multiple sclerosis. Int J MS Care 25(5):196–198

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kumar A, Khamkar K, Gopal H (2012) Serum sickness and severe angioedema following Rituximab therapy in RA. Int J Rheum Dis 15(1):e6–e7

    Article  PubMed  Google Scholar 

  5. Bayer G, Agier MS, Lioger B et al (2019) Rituximabinduced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study. Eur J Intern Med 67:59–64

    Article  CAS  PubMed  Google Scholar 

  6. Holmoy T, Fogdell-Hahn A, Svenningsson A (2019) Serum sickness following rituximab therapy in multiple sclerosis. Neurol Clin Pract 9(6):519–521

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wolf AB, Ryerson LZ, Pandey K et al (2019) Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord 36:101402

    Article  PubMed  Google Scholar 

  8. Krumbholz M, Pellkofer H, Gold R et al (2007) Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 64(9):1331–1333

    Article  PubMed  Google Scholar 

  9. Lapucci C, Gualandi F, Mikulska M et al (2018) Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: a case report. Mult Scler Relat Disord 26:52–54

    Article  CAS  PubMed  Google Scholar 

  10. Saba J, Logan AC (2017) Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia. Clin Case Rep 5(6):891–893

    Article  PubMed  PubMed Central  Google Scholar 

  11. Elmanaseer O, Avelino ARM, Azem A et al (2021) Serum sickness reaction to obinutuzumab in a patient with chronic lymphocytic leukaemia. BMJ Case Rep 14(12):e245557

    Article  PubMed  PubMed Central  Google Scholar 

  12. Joubert M, Paris P, Clavelou P et al (2021) Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: a case report. Rev Neurol (Paris) 177(8):1041–1042

    Article  CAS  PubMed  Google Scholar 

  13. Doyle AJ, Stubbs MJ, Lester W et al (2022) The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura. Br J Haematol 198(2):391–396

    Article  CAS  PubMed  Google Scholar 

  14. Rapp M, Pentland A, Richardson C (2018) Successful treatment of pemphigus vulgaris with ofatumumab. J Drugs Dermatol 17(12):1338–1339

    PubMed  Google Scholar 

  15. Podestà MA, Ruggiero B, Remuzzi G, Ruggenenti P (2023) Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. BMJ Case Rep 13(1):e232896

    Article  Google Scholar 

  16. Al-Araji S, Ciccarelli O (2021) A possible case of serum sickness after ocrelizumab infusion - Commentary. Mult Scler 27:158–159

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MS Center, Department of Neurology, ASST Lecco, Via dell’Eremo 9/11, 23900, Lecco, Italy

    Vittorio Mantero, Roberto Balgera, Paola Basilico & Andrea Salmaggi

  2. UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA

    Christian Cordano

  3. Department of Neurosciences, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

    Giovanni Novi

Authors
  1. Vittorio Mantero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Cordano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Balgera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paola Basilico
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Novi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Salmaggi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

VM contributed to the conceptualization, gathering of data and drafting the manuscript; CC, PB, RB, and GN contributed to gathering of data and drafting the manuscript; AS contributed to drafting and revising the manuscript.

Corresponding author

Correspondence to Vittorio Mantero.

Ethics declarations

Conflicts of interest

The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

The patient provided consent to be anonymously included in this report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mantero, V., Cordano, C., Balgera, R. et al. Serum sickness in a multiple sclerosis patient treated with ocrelizumab. J Neurol 271, 727–728 (2024). https://doi.org/10.1007/s00415-023-12082-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-023-12082-6

Search

Navigation